Radnor Capital Management LLC Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Radnor Capital Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 34,335 shares of the company’s stock after selling 150 shares during the period. Johnson & Johnson makes up 1.5% of Radnor Capital Management LLC’s investment portfolio, making the stock its 11th largest holding. Radnor Capital Management LLC’s holdings in Johnson & Johnson were worth $4,442,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Billeaud Capital Management Inc. lifted its position in Johnson & Johnson by 0.4% in the 2nd quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after acquiring an additional 169 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 11.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock valued at $15,277,000 after acquiring an additional 10,927 shares during the last quarter. Archford Capital Strategies LLC lifted its holdings in shares of Johnson & Johnson by 11.2% in the 2nd quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock valued at $3,064,000 after acquiring an additional 2,211 shares during the last quarter. Marino Stram & Associates LLC lifted its holdings in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock valued at $4,485,000 after acquiring an additional 380 shares during the last quarter. Finally, Palisades Hudson Asset Management L.P. lifted its holdings in shares of Johnson & Johnson by 42.6% in the 2nd quarter. Palisades Hudson Asset Management L.P. now owns 2,241 shares of the company’s stock valued at $312,000 after acquiring an additional 669 shares during the last quarter. Institutional investors own 72.01% of the company’s stock.

JNJ stock traded down $1.31 during trading on Monday, hitting $132.35. 628,949 shares of the company’s stock traded hands, compared to its average volume of 6,806,219. The firm has a market capitalization of $346.23 billion, a P/E ratio of 16.18, a PEG ratio of 2.22 and a beta of 0.69. The business has a fifty day simple moving average of $129.81 and a two-hundred day simple moving average of $135.16. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period in the previous year, the company earned $2.10 earnings per share. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.87%. Johnson & Johnson’s payout ratio is currently 46.45%.

A number of brokerages recently commented on JNJ. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 27th. Raymond James lowered their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a report on Wednesday, July 17th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a report on Thursday, July 18th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What are gap-down stocks?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.